Clinical trials are conducted to collect data regarding the safety and efficacy of new drug and device development. Treatments studied in clinical trials might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. Office visits, lab test, medication, study related procedures, and compensation for time and travel are provided to eligible participants.
CURRENT CLINICAL STUDIES
A Phase II, Patient blinded, Two-part, Randomized, Parallel-group Trial to Evaluate the Safety, Tolerability, Pharmacokinetic, and Efficacy of LYR-220 in Chronic Rhinosinusitis (CRS) Patients Who Have Had a Prior Ethmoidectomy.
To see if you qualify or for more information call 210-545-0404 ext. 1324 and reference clinical study LYR-220-2021-001.
Phase III, Randomized, Blinded, Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis (CRS) in Adults.
To see if you qualify or for more information call 210-545-0404 ext. 1324 and reference clinical study LYR-210-2021-004.
Learn More About This Study
CHRONIC RHINOSINUSITIS without NASAL POLYPS:
Sanofi EFC16723, a randomized, double-blind, placebo-controlled, 2-part study to evaluate the efficacy and safety of dupilumab in patients with uncontrolled, chronic rhinosinusitis without nasal polyposis (CRSsNP).
To see if you qualify or for more information call 210-545-0404 ext. 1324. Sanofi EFC16723.
Frequency FX-345-101 A Phase 1b, Prospective, Randomized, Single-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety of FX-345 Administered as a Single Intratympanic Injection in Adults with Acquired Adult-Onset Sensorineural Hearing Loss.
To see if you qualify or for more information call 210-545-0404 ext. 1324 and reference clinical study Frequency FX-345-101.
FX-322-208, a Phase 2, prospective, randomized, double-bling, placebo-controlled, single-dose, multicenter study to evaluate the efficacy of FX-322, administered by intratympanic injection, in adults with acquired sensorineural hearing loss (SNHL).
Previous human studies in subjects 18 to 65 years inclusive (FX-322-103, FX-322-201, FX-322-111) and subjects inclusive (FX-322-112) demonstrated that a single dose FX-322 was well tolerated in patients with acquired SNHL with no treatment-related serious adverse events.
To see if you qualify or for more information call 210-545-0404 ext. 1324 and reference clinical study FX-322-208.
CHRONIC RHINISITIS with NASAL POLYPOSIS:
GSK 218079, A randomised, double-blind, parallel group Phase III study to assess the efficacy and safety of 100 mg SC depemokimab in patients with chronic rhinosinusitis
with nasal polyps (CRSwNP) – ANCHOR-2 (depemokimAb iN CHrOnic Rhinosinusitis)
ALLERGIC FUNGAL RHINOSINUSITIS:
Sanofi EFC16724, a randomized double-blind placebo-controlled parallel group study assessing the efficacy and safety of dupilumab in patients with Allergic Fungal Rhinosinusitis (AFRS).
To see if you qualify or for more information call 210-545-0404 ext. 1324 and reference Sanofi EFC16724.
Our team can answer questions, discuss your needs and help locate research studies that match your interests.
We can also provide interpreter services for non-English speaking patients. Call 210-545-0404 ext. 1324
CLINICAL RESEARCH TEAM
Primary Investigator: Dr. Jeffrey Rosenbloom
Sub Investigator: Dr. Benjamin Webb
Senior Research Coordinator: Robert Gonzalez, LVN
Phone: 210-545-0404 ext. 1324
Clinical Research Coordinator: Frank Morales, MA
Phone: 210-545-0404 ext. 1328